⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8791559 | 0.63 | — | — | |
| SCHEMBL499558 | 0.61 | — | — | |
| SCHEMBL7502426 | 0.60 | — | — | |
| SCHEMBL8355693 | 0.60 | — | — | |
| SCHEMBL2105621 | 0.55 | — | — | |
| SCHEMBL309103 | 0.52 | — | — | |
| SCHEMBL3171628 | 0.42 | — | — | |
| Hydrogen Sulfide SCHEMBL18858709 | 0.36 | — | — | |
| SCHEMBL31175398 | 0.35 | — | — | |
| SCHEMBL25289269 | 0.32 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | claimed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | claimed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | claimed |
| US-11840529-B2 | Substituted pyrimidines as LRKK2 inhibitors | DENALI THERAPEUTICS INC. (US) | 2023-12-12 | — | — | US | claimed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| US-11814338-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | claimed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-4791120-A | ANALGESICS | THE BOC GROUP, INC. (US) | 1988-12-13 | — | — | US | claimed |
| US-4616007-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1986-10-07 | — | — | US | claimed |
| EP-0150891-A1 | Tricyclic compounds, processes for their preparation, compositions containing such compounds and their use in medicine | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-08-07 | — | — | EP | claimed |
| EP-0112283-A1 | Heterocyclyl-thio compounds, process for their preparation, pharmaceutical compositions containing them and their use | CIBA-GEIGY AG (CH) | 1984-06-27 | — | — | EP | claimed |
| EP-0109362-A1 | Hetereocyclic compounds, process for their preparation, pharmaceutical compositions containing them and their use | CIBA-GEIGY AG (CH) | 1984-05-23 | — | — | EP | claimed |
| US-4125611-A | MICROBIOCIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1978-11-14 | — | — | US | claimed |
| US-4118566-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-10-03 | — | — | US | claimed |
| US-4068080-A | BETA-LACTAM ANTIBIOTICS, CEPHALOSPORIN ANALOGS | BRISTOL-MYERS COMPANY (US) | 1978-01-10 | — | — | US | claimed |
| US-4061748-A | BACTERICIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-12-06 | — | — | US | claimed |
| US-4013648-A | BETA-LACTAM ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1977-03-22 | — | — | US | claimed |